Emergent BioSolutions (EBS) Assets (2010 - 2026)
Emergent BioSolutions (EBS) reported Assets of $1.12 billion for Q2 2026, down 21.2% from $1.42 billion a year earlier and down 15.4% from the prior quarter.
Powered by 
Analysis
Emergent BioSolutions (EBS) Assets (2010 - 2026) Analysis & Trends
At the end of FY2025, Emergent BioSolutions posted Assets of $1.32 billion, down 5.1% from FY2024.
- Assets has declined for three consecutive years, with a five-year compound annual growth rate of -14.5% (FY2020 to FY2025).
- By year, Assets came in at $1.39 billion in FY2024 (-23.8%), $1.82 billion in FY2023 (-42.4%), $3.17 billion in FY2022 (+7.1%) and $2.96 billion in FY2021 (+2.6%).
- The Q2 2026 figure ranks as the lowest quarterly Assets since Q1 2018.
- Year over year, Assets has now declined in each of the last 13 quarters, with an average decline of 13.5% over the last eight quarters.
- The high point for year-over-year Assets in five years was Q3 2021 (growth of 9.6%); the low point was Q4 2023 (a decline of 42.4%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $1.32 billion (Q1 2026), $1.32 billion (Q4 2025) and $1.46 billion (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,146.94 Bn | 1,115.53 Bn | 19.71 Bn | 142.28 Bn |
| 2 | Johnson & Johnson | 624.96 Bn | 543.49 Bn | 17.26 Bn | 201.06 Bn |
| 3 | AbbVie | 510.15 Bn | 483.27 Bn | 12.70 Bn | 135.12 Bn |
| 4 | Merck | 366.13 Bn | 320.51 Bn | 12.21 Bn | 129.80 Bn |
| 5 | Novartis Ag | 297.75 Bn | 261.74 Bn | 11.24 Bn | 122.03 Bn |
| 6 | Astrazeneca | 261.93 Bn | 235.62 Bn | 12.86 Bn | 115.83 Bn |
| 7 | Amgen | 236.51 Bn | 191.91 Bn | 7.24 Bn | 95.64 Bn |
| 8 | Gilead Sciences | 194.27 Bn | 168.47 Bn | 6.22 Bn | 49.36 Bn |
| 9 | Pfizer | 171.74 Bn | 118.39 Bn | 10.94 Bn | 201.13 Bn |
| 10 | Emergent BioSolutions | 325.34 Mn | -425.56 Mn | 137.20 Mn | 1.12 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.12 Bn |
| Mar 31, 2026 | 1.32 Bn |
| Dec 31, 2025 | 1.32 Bn |
| Sep 30, 2025 | 1.46 Bn |
| Jun 30, 2025 | 1.42 Bn |
| Mar 31, 2025 | 1.43 Bn |
| Dec 31, 2024 | 1.39 Bn |
| Sep 30, 2024 | 1.48 Bn |
| Jun 30, 2024 | 1.51 Bn |
| Mar 31, 2024 | 1.80 Bn |
| Dec 31, 2023 | 1.82 Bn |
| Sep 30, 2023 | 1.89 Bn |
| Jun 30, 2023 | 2.18 Bn |
| Mar 31, 2023 | 2.95 Bn |
| Dec 31, 2022 | 3.17 Bn |
| Sep 30, 2022 | 2.90 Bn |
| Jun 30, 2022 | 2.74 Bn |
| Mar 31, 2022 | 2.78 Bn |
| Dec 31, 2021 | 2.96 Bn |
| Sep 30, 2021 | 2.87 Bn |
API Access
Emergent BioSolutions Assets API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=assets&ticker=EBS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "assets", "ticker": "EBS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=assets&ticker=EBS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();